iih glp-1 Novel use of receptor agonist therapy for pediatric idiopathic intracranial hypertension: a case report NeuroOp Guru: Stopping GLP-1 therapy
Description
Doustdar thinks the drug's edge in effectiveness over Wegovy, even if only a few percentage points, is meaningful, and said he's committed to launching CagriSema
Dan Skovronsky, director cientfico y de productos de Lilly
The digestive changes caused by GLP-1 medications may also affect how efficiently the body processes certain foods, which could contribute to the development of sulphur-smelling burps in some patients
FDA approval impact When Eli Lilly secures FDA approval, the commercial product will likely launch at $1,000 to $1,500 per month
